目的:Lasmiditan在治疗偏头痛方面具有重要潜力,但它的理想剂量仍然难以捉摸。这项荟萃分析是基于汇总数据进行的,旨在比较200mg与100mg的lasmiditan对偏头痛发作的急性治疗的疗效。
方法:PubMed,Embase,WebofScience,EBSCO,对Cochrane图书馆数据库进行了系统搜索,我们纳入了随机对照试验,比较了200mg与100mgLasmiditan对偏头痛患者的疗效.该荟萃分析使用基于异质性的随机效应模型或固定效应模型进行。主要结果是2小时无痛。次要结果包括2小时疼痛缓解,24小时无痛,最烦人的症状在2小时内就没有了,和不良事件。
结果:7项随机对照试验和6515例患者被纳入这项荟萃分析。与偏头痛患者的Lasmiditan100mg相比,Lasmiditan200mg能够在2小时内显着改善无痛(奇数比率[OR],1.28;95%置信区间[CI],1.14-1.44;P<0.0001)和24小时无痛(OR,1.35;95%CI,1.14-1.60;P=0.0005),但在2小时时对疼痛缓解没有影响(或,1.00;95%CI,0.90-1.12;P=0.98)或在2小时时没有最烦人的症状(OR,0.93;95%CI,0.83-1.03;P=0.17)。与Lasmiditan100mg相比,Lasmiditan200mg与不良事件的增加有关(OR,1.28;95%CI,1.15-1.43;P<0.0001)。
结论:对于偏头痛患者的急性治疗,Lasmiditan200mg比Lasmiditan100mg更有效地改善2小时和24小时的无痛。
OBJECTIVE: Lasmiditan holds important potential in treating migraine, but its ideal dose remains elusive. This meta-analysis is conducted based on aggregate data and aims to compare the efficacy of lasmiditan 200 mg versus 100 mg for acute treatment of migraine attack.
METHODS: PubMed, Embase, Web of Science, EBSCO, and Cochrane Library databases were systematically searched, and we included the randomized controlled trials comparing the efficacy of lasmiditan 200 mg versus 100 mg for migraine patients. This meta-analysis was conducted using the random-effect model or fixed-effect model based on the heterogeneity. The primary outcome was pain free at 2 hours. Secondary outcomes included pain relief at 2 hours, pain free at 24 hours, most bothersome symptom free at 2 hours, and adverse events.
RESULTS: Seven randomized controlled trials and 6515 patients were included in this meta-analysis. Compared with lasmiditan 100 mg for migraine patients, lasmiditan 200 mg was able to significantly improve pain free at 2 hours (odd ratio [OR], 1.28; 95% confidence interval [CI], 1.14-1.44; P < 0.0001) and pain free at 24 hours (OR, 1.35; 95% CI, 1.14-1.60; P = 0.0005), but showed no effect on pain relief at 2 hours (OR, 1.00; 95% CI, 0.90-1.12; P = 0.98) or most bothersome symptom free at 2 hours (OR, 0.93; 95% CI, 0.83-1.03; P = 0.17). Lasmiditan 200 mg was associated with the increase in adverse events compared with lasmiditan 100 mg (OR, 1.28; 95% CI, 1.15-1.43; P < 0.0001).
CONCLUSIONS: Lasmiditan 200 mg is more effective to improve pain free at 2 hours and 24 hours than lasmiditan 100 mg for the acute treatment of migraine patients.